We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| GT Biopharma Inc | NASDAQ:GTBP | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.14 | -3.59% | 3.76 | 3.77 | 3.89 | 4.09 | 3.56 | 4.05 | 52,121 | 15:21:24 |
From May 2021 to May 2024
BEVERLY HILLS, Calif, June 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that GT Biopharma CEO, Tony Cataldo will be presenting as a VIP speaker at the upcoming Sir Anthony Ritossa's Global Family Office Investment Summit in Monaco from June 30 to July 2, 2021.
The Sir Anthony Ritossa's Global Family Office Investment Summit in Monaco is one of a series of international summits held annually as a platform for exceptional networking between Family Offices and Thought Leaders from all over the world. Summit delegations consist of prestigious family offices, private investors, sheikhs, royal families and leading businesses from 30+ countries representing more than $4.5 trillion in wealth.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology. For more information, please visit gtbiopharma.com.
Investor Contact: | Investor and Media Relations Contact: |
Brendan Payne | David Castaneda |
Client Lead | David@gtbiopharma.com |
Stern Investor Relations, Inc. | 414-351-9758 |
brendan.payne@sternir.com | |
212-362-1200 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/gt-biopharma-ceo-tony-cataldo-to-present-at-sir-anthony-ritossas-global-family-office-investment-summit-301318854.html
SOURCE GT Biopharma, Inc.
Copyright 2021 PR Newswire
1 Year GT Biopharma Chart |
1 Month GT Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
